USRM Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 22:42):

Stats
Dzisiejszy wolumen	102 475
Średni wolumen	8 048.00
Kapitalizacja rynkowa	642.00
EPS	$-0.000960 ( 2022-12-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-04-25	Knutson Gregory	Buy	2 500 000	Common Stock
2022-03-18	Knutson Gregory	Buy	25 000 000	Common Stock
2022-02-24	Knutson Gregory	Buy	12 500 000	Warrant
2022-02-24	Knutson Gregory	Buy	12 500 000	Convertible promissory Note (right to buy)
2021-03-23	Murphy William P Jr	Buy	7 518 797	Common Stock

INSIDER POWER
100.00
Last 99 transactions
Buy: 237 671 429 \| Sell: 625 000

U.S. Stem Cell, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

U.S. Stem Cell, Inc. Finanse

Annual	2022
Przychody:	$82 049.00
Zysk brutto:	$58 282.00 (71.03 %)
EPS:	$-0.00560

FY	2022
Przychody:	$82 049.00
Zysk brutto:	$58 282.00 (71.03 %)
EPS:	$-0.00560

FY	2021
Przychody:	$200 749
Zysk brutto:	$148 719 (74.08 %)
EPS:	$-0.00800

FY	2020
Przychody:	$277 087
Zysk brutto:	$212 970 (76.86 %)
EPS:	$-0.00673

Financial Reports:

No articles found.

U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.